Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.00)
# 2,990
Out of 4,935 analysts
55
Total ratings
32.65%
Success rate
-1.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $16.31 | +298.53% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $9.24 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $16.94 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.63 | - | 1 | Mar 18, 2025 | |
| MTSR Metsera | Initiates: Overweight | n/a | $30.40 | - | 1 | Feb 25, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $13.67 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $5.30 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $3.97 | +151.89% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $345.73 | - | 4 | Nov 20, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $52.22 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $50.46 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.81 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $26.71 | -10.15% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.47 | +18,118.62% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.50 | +2,727.14% | 1 | Mar 3, 2021 |
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $16.31
Upside: +298.53%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.24
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $16.94
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.63
Upside: -
Metsera
Feb 25, 2025
Initiates: Overweight
Price Target: n/a
Current: $30.40
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $13.67
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.30
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $3.97
Upside: +151.89%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $345.73
Upside: -
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $52.22
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $50.46
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $9.81
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $26.71
Upside: -10.15%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.47
Upside: +18,118.62%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.50
Upside: +2,727.14%